title: Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy.
abstract: OBJECTIVE
  To evaluate chemoprevention by celecoxib in cases of reflux-induced gastric adenocarcinoma, in Wistar rats that underwent gastrojejunostomy.
  
  
  METHODS
  Sixty male Wistar rats of average age three months underwent surgery and were distributed into three groups: group 1, exploratory laparotomy; group 2, gastrojejunostomy; and group 3, gastrojejunostomy and daily celecoxib administration. After 53 weeks, the animals were sacrificed. Changes in the mucosa of the gastric body of group 1 and in the gastrojejunal anastomosis of groups 2 and 3, observed in histopathological and immunohistochemical examinations, were compared. All statistical analyses were performed using Epi-Info, version 3.4.3.
  
  
  RESULTS
  Comparison between groups 2 and 3 relative to the presence of adenocarcinoma showed a statistically significant difference (p=0.0023). Analysis of the association between groups 2 and 3 relative to COX-2 expression also showed a statistically significant difference (p=0.0018).
  
  
  CONCLUSIONS
  Celecoxib had an inhibiting effect on gastric carcinogenesis induced by enterogastric reflux in an animal model.
authors.affiliation: Department of Surgery, Federal University of Alagoas, Brazil.
authors.forename: Frederico Theobaldo Ramos
authors.initials: FT
authors.lastname: Rocha
authors.forename: Laercio Gomes
authors.initials: LG
authors.lastname: Lourenço
authors.forename: Mário Jorge
authors.initials: MJ
authors.lastname: Jucá
authors.forename: Valéria
authors.initials: V
authors.lastname: Costa
authors.forename: Antenor Teixeira
authors.initials: AT
authors.lastname: Leal
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004383:Duodenogastric Reflux / Q000150:complications* / Q000601:surgery; D015390:Gastric Bypass; D006965:Hyperplasia; D008297:Male; D016017:Odds Ratio; D011720:Pyrazoles / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib